论文部分内容阅读
为进一步研究抗着丝粒抗体(ACA)和抗局部同分异构酶I(topoisomerase I,简称topo I)抗体与临床的联系,作者对355例病人的血清进行了研究。其中89例为近心端硬皮病,54例CREST综合征,154例原发或继发性雷诺氏病。另58例患SLE、干燥综合征或RA,但无雷诺氏现象,任何CREST 表现、皮肤变厚或发紧,这些病人作为结缔组织病(CTD)的对照组。34名健康人为另一对照组。以HEp-2细胞作底物,用间接免疫荧光法测ACA;以免疫扩散法测抗topo I(Scl-70)抗体;以提纯的HeLa 细胞染色体作为底物,用免疫印迹法检测ACA 及抗topo I。结果:①CTD 对照组及健康人对照组ACA 阴件,仅1名健康人用免疫印迹法检测抗topo I 抗体,结果阳性,CTD 对照组未检出此抗体。用两
To further investigate the clinical relevance of anti-centromere antibody (ACA) and anti-topoisomerase I (topo I) antibodies, 355 patients’ sera were studied. Among them 89 cases were proximal scleroderma, 54 cases of CREST syndrome and 154 cases of primary or secondary Raynaud’s disease. The other 58 patients had SLE, Sjogren’s syndrome or RA, but no Raynaud’s phenomenon, any CREST appearance, thickening or tightening of the skin, and these patients served as a control group for connective tissue disease (CTD). 34 healthy people as another control group. ACA was detected by indirect immunofluorescence assay using HEp-2 cells as a substrate. Anti-topo I (Scl-70) antibody was detected by immunodiffusion method. Purified HeLa cells were used as substrate to detect ACA and anti- topo I. Results: ①CTD control group and healthy control group ACA negative, only a healthy person with anti-topo I antibody by immunoblotting, the result was positive, CTD control group did not detect this antibody. Use two